Advertisement

Neurocritical Care

, Volume 24, Issue 3, pp 413–419 | Cite as

The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage

  • Jamil R. Dibu
  • Jonathan M. Weimer
  • Christine Ahrens
  • Edward Manno
  • Jennifer A. Frontera
Original Article

Abstract

Background

Activated prothrombin complex concentrates factor eight inhibitor bypassing activity (FEIBA) has been recommended for reversing novel oral anticoagulants (NOAC) in the context of intracerebral hemorrhage (ICH), though few clinical studies report its use.

Methods

A prospective study of patients with spontaneous ICH was conducted from May 2013 to May 2015. Hospital complications including hemorrhage (gastrointestinal bleeding, anemia requiring transfusion, and surgical site bleeding) and thrombosis (pulmonary embolus, deep vein thrombosis, ischemic stroke, and myocardial infarction) were recorded. All ICH patients underwent baseline head CT and a follow-up stability scan in 6 h. NOAC taken within 48 h of presentation was reversed with FEIBA (50 u/kg) per protocol. Three-month outcomes were assessed using the modified rankin score (mRS).

Results

Of 127 ICH patients enrolled, 6 (5 %) had NOAC-related ICH including: oral factor XA inhibitor N = 5 (4 %; N = 4 rivaroxaban, N = 1 apixaban] and direct thrombin inhibitor N = 1 (0.8 %; dabigatran). The indication for NOAC was atrial fibrillation in all patients and the median CHADS2–VASC score was 4 (range 2–5). The median admission NIHSS was 2 (range 0–14) and the median ICH volume was 8 mL (range 1–20). Five patients (3 rivaroxaban, 1 apixaban, 1 dabigatran) presented within 48 h and received FEIBA within a median of 13 h (range 10–29 h) from their last NOAC dose and 8 h (range 4.5–20) from the time last known well. None of the patients had ICH expansion, hemorrhagic, or thrombotic complications. Three-month median mRS was 1 (range 0–6).

Conclusion

In this small case series, reversal of NOAC with FEIBA was not associated with ICH expansion or any thrombotic or hemorrhagic complications.

Keywords

Intracerebral hemorrhage Novel oral anticoagulants Activated prothrombin complex concentrate Anticoagulant-related intracerebral hemorrhage reversal 

Notes

Complaince with Ethical Standards

Conflict of Interest

The authors have nothing to disclose.

References

  1. 1.
    Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation. 2011;124:1982–93.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient metaanalysis. JAMA. 2003;288:2441–8.CrossRefGoogle Scholar
  3. 3.
    Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage facts and hypotheses. Stroke. 1995;26:1471–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. doi: 10.1056/NEJMoa0905561 published correction appears in N Engl J Med. 2010;363:1877.CrossRefPubMedGoogle Scholar
  5. 5.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. doi: 10.1056/NEJMoa1009638.CrossRefPubMedGoogle Scholar
  6. 6.
    Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, GonzalezHermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17. doi: 10.1056/NEJMoa1007432.CrossRefPubMedGoogle Scholar
  7. 7.
    Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486–90. doi: 10.1001/jamaneurol.2013.4021.PubMedGoogle Scholar
  8. 8.
    Hemphill JC III, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung G, Goldstein J, Macdonald L, Mitchell P, Scott P. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2032.CrossRefPubMedGoogle Scholar
  9. 9.
    Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004;10(Suppl 2):3–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217–24.CrossRefPubMedGoogle Scholar
  11. 11.
    Perzborn E, Heitmeier S, Laux V, Buchmuller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res. 2014;133(4):671–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Schulman S, Ritchie B, Goy JK, Nahirniak S, Almutawa M, Ghanny S. Activated prothrombin complex concentrate for dabigatran-associated bleeding. Br J Haematol. 2013;164:296–310.Google Scholar
  13. 13.
    Wong H, Keeling D. Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding. Br J Haematol. 2014;166:140–53.CrossRefGoogle Scholar
  14. 14.
    Puttick T, Bahl R, Mohamedbhai H. Emergency reversal of dabigatran for emergency surgery. BMJ Case Rep. 2015. doi: 10.1136/bcr-2014-209057.PubMedGoogle Scholar
  15. 15.
    Dager W, Roberts A. Reversing dabigatran with FEIBA in a patient with a transseptal perforation during cardiac ablation. Crit Care Med. 2011;39(12):243.Google Scholar
  16. 16.
    Heidbuchel H, Verhamme P, Alings M, et al. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625–51.CrossRefPubMedGoogle Scholar
  17. 17.
    Meyer CS, Blebea J, Davis K Jr, Fowl RJ, Kempczinski RF. Surveillance venous scans for deep venous thrombosis in multiple trauma patients. Ann Vasc Surg. 1995;9(1):109–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S–77S. doi: 10.1378/chest.11-2297.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kiraly A, Lyden A, Periyanayagam U, Chan J, Pang P. Management of hemorrhage complicated by novel oral anticoagulants in the emergency department: case report from the northwestern emergency medicine residency. Am J Ther. 2013;20:300–6.PubMedGoogle Scholar
  20. 20.
    Maurice-Szamburski A, Graillon T, Bruder N. Favorable outcome after subdural hematoma treated with FEIBA in a 77-year-old patient treated by rivaroxaban. J Neurosurg Anesthesiol. 2014;26:2.CrossRefGoogle Scholar
  21. 21.
    Lindahl TL, Wallstedt M, Gustafsson KM, Persson E, Hillarp A. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. Thromb Res. 2015;135(3):544–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S. The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol. 2013;35(2):222–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA)-addressing safety issues. Haemophilia. 2008;14:39–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8(3):280–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Glund S, Stangier J, Schmohl M, De Smet M, Gansser D, Lang B, Moschetti V, Ramael S, Reilly P. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation. 2013;128:A17765.Google Scholar
  26. 26.
    Glund S, Stangier J, Schmohl M, Moschetti V, Haazen W, Gansser M, Norris S, Lang B, Reilly P. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood. 2014;124:A344.CrossRefGoogle Scholar
  27. 27.
    Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015. doi: 10.1056/NEJMoa1502000.PubMedGoogle Scholar
  28. 28.
    Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–51.CrossRefPubMedGoogle Scholar
  29. 29.
    Crowther M, Vandana M, Michael K, et al. A Phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors. 55th ASH annual meeting, New Orleans 2013.Google Scholar
  30. 30.
    Crowther M, Levy G, Lu G, Leeds J, Barron L, Conley P, Castillo J, Curnutte J, Connolly S. ANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alpha (PRT064445), a universal antidote for factor Xa (fXa) Inhibitors. Circulation. 2014;130:2105.CrossRefGoogle Scholar
  31. 31.
    Laulicht B, Bakhru S, Jiang X, et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at the 24th Congress of the International Society on Thrombosis and Haematosis, Amsterdam, June 29–July 4, 2013.Google Scholar
  32. 32.
    Bakhru S, Laulicht B, Jiang X, Chen L, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S. PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation. 2014;128:A18809.Google Scholar
  33. 33.
    Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141–2. doi: 10.1056/NEJMc1411800.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Jamil R. Dibu
    • 1
  • Jonathan M. Weimer
    • 1
  • Christine Ahrens
    • 1
  • Edward Manno
    • 1
  • Jennifer A. Frontera
    • 1
  1. 1.Cerebrovascular Center of the Neurological InstituteCleveland ClinicClevelandUSA

Personalised recommendations